生产工程师
百奥泰生物制药股份有限公司
- 公司规模:500-1000人
- 公司性质:合资
- 公司行业:制药/生物工程
职位信息
- 发布日期:2019-11-06
- 工作地点:广州-黄埔区
- 招聘人数:2人
- 工作经验:3-4年经验
- 学历要求:本科
- 职位月薪:10-50万/年
- 职位类别:药品生产/质量管理 生物工程/生物制药
职位描述
1、 负责组织对各产线出现的偏差事件进行调查,并撰写偏差调查报告;
2、 负责各产线与GMP相关的变更活动执行;
3、 负责组织各产线完成各项验证工作,编写验证方案/报告;
4、 负责修订完善通用生产管理文件;
5、 参与各产线的新建/改建项目;
6、 参与对各产线GMP合规性自检;
7、 组织各产线人员定期开展法规、GMP活动流程培训;
8、 其他临时性工作。 任职要求:
1、 药学或生物制药及相关专业,本科及以上学历;
2、 有3-5年从药经历或1 年以上同岗位经历,有单抗或无菌药品工作经历优先;
3、 熟悉GMP法规/指南及各项质量活动流程;
4、 有较好的分析能力,逻辑思维清晰;
5、 有较强的组织协调能力和沟通表达能力。
公司介绍
百奥泰生物制药股份有限公司(股票代码:688177)秉承“创新只为生命”的理念,致力于开发新一代创新药和生物类似药,用于治疗肿瘤、自身免疫性疾病、心血管疾病以及其它危及人类生命或健康的重大疾病。公司已推动五款候选药物进入后期临床试验,其中格乐立(阿达木单抗)已在中国获批用于治疗类风湿关节炎、强直性脊柱炎、银屑病、克罗恩病和葡萄膜炎。此外,公司另有多款主攻肿瘤和自身免疫性疾病的候选药物处于不同的临床开发阶段。公司始终以患者的福祉作为首要核心价值,通过创新研发为患者提供安全、有效、可负担的优质药物,以满足亟待解决的治疗需求。欲了解更多信息,请访问公司官网或关注我们的微信公众号“百奥泰”。
Bio-Thera?Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to?Humira?(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,?Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
Bio-Thera?Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to?Humira?(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,?Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
联系方式
- Email:bd@bio-thera.com
- 公司地址:广州科学城开源大道11号科技企业加速器A6幢5楼 (邮编:510530)